Details of Disease

General Information of Disease (ID: DIS48ZAP)

Disease Name	Allergy
Synonyms	allergic hypersensitivity disease; hypersensitivity; disorder of type I hypersensitivity; allergic reaction; allergic response; allergic form of disease or disorder; hypersensitivity reaction type I disease; allergic form of immune system disease; allergy; allergic disease or disorder; type I hypersensitivity disease
Disease Class	4A80-4A8Z: Allergic/hypersensitivity disorder
Definition	An immune response that occurs following re-exposure to an innocuous antigen, and that requires the presence of existing antibodies against that antigen. This response involves the binding of IgE to mast cells, and may worsen with repeated exposures.
Disease Hierarchy	DISWD40R: Disease DISEDL2I: Hypersensitivity DIS48ZAP: Allergy
ICD Code	ICD-11 ICD-11: 4A80-4A85 ICD-10 ICD-10: T78.4 ICD-9 ICD-9: 995.3 Expand ICD-11 '4A8Z Expand ICD-10 'T78.4 Expand ICD-9 995.3
Disease Identifiers	MONDO ID MONDO_0005271 MESH ID D006967 UMLS CUI C0020517 MedGen ID 9370 HPO ID HP:0012393 SNOMED CT ID 421961002

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 13 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Acellular pertussis vaccine	DMLKYAQ	Approved	NA	[1]
Acitazanolast	DM23YO2	Approved	Small molecular drug	[1]
Chanllergen	DMHOIK4	Approved	NA	[1]
Epinephrine	DM3KJBC	Approved	Small molecular drug	[2]
Gamolenic acid	DMQN30Z	Approved	Small molecular drug	[1]
Loratadine	DMF3AN7	Approved	Small molecular drug	[3]
Mepyramine	DMB4SFH	Approved	Small molecular drug	[4]
Mepyramine maleate	DM7F5OW	Approved	Small molecular drug	[5]
MK-3641	DMTAGIP	Approved	NA	[6]
MPL-containing Pollinex allergy desensitization vaccine	DMTE90L	Approved	NA	[1]
Mumps skin test antigen	DMWPWL8	Approved	NA	[1]
Phenyltoloxamine	DMKAEQW	Approved	Small molecular drug	[1]
Suplatast tosilate	DMOGREH	Approved	Small molecular drug	[7]
------------------------------------------------------------------------------------


⏷ Show the Full List of 13 Drug(s)

This Disease is Treated as An Indication in 33 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
MPL-containing Pollinex allergy desensitization vaccine	DMXSDJU	Preregistration	Vaccine	[8]
AR101	DM295IJ	Phase 3	NA	[9]
Cat peptide allergy desensitization agent	DM34YR4	Phase 3	NA	[10]
Grass pollen immunotherapy	DMNZ13F	Phase 3	NA	[11]
MPL-containing Pollinex allergy desensitization vaccine	DMT35Z1	Phase 3	NA	[12]
Peanut allergy desensitization vaccine	DMM3FRO	Phase 3	NA	[9]
Polymerized vaccine	DM1DBTC	Phase 3	NA	[13]
Ragweed pollen extract	DM710IZ	Phase 3	NA	[14]
AllerB	DM78DOT	Phase 2b	NA	[15]
AbGn-168	DMT6H3J	Phase 2	Antibody	[16]
AllerT	DM5Z0HH	Phase 2	NA	[17]
Dust mite peptide allergy desensitization	DM0G2YJ	Phase 2	NA	[18]
Grass peptide allergy desensitization agent	DM862NI	Phase 2	NA	[19]
JTE-051	DM2LBHN	Phase 2	NA	[20]
Mam-06.301	DMS0DD5	Phase 2	NA	[21]
OC-000459	DM1JBD8	Phase 2	Small molecular drug	[22]
PEGylated pitrakinra	DMBPJ9U	Phase 2	Monoclonal antibody	[23]
Ragweed peptide allergy desensitization	DMDM9EZ	Phase 2	NA	[24]
Recombinant vaccine	DMF4HEK	Phase 2	NA	[25]
S-555739	DMXDVNZ	Phase 2	NA	[26]
Short ragweed pollen extracts	DMWL7BW	Phase 2	NA	[27]
Viaskin Milk	DMOHMVL	Phase 2	NA	[9]
IMP-321	DM18ZLW	Phase 1/2	NA	[28]
Allergy immunotherapeutic vaccine	DMW2DTA	Phase 1	NA	[9]
ASP0892	DMXOQBG	Phase 1	Vaccine	[9]
Cat hair allergen extract	DM2YFBB	Phase 1	NA	[29]
CR-3465	DMT7L30	Phase 1	NA	[30]
HAL-MPE1	DMICO1C	Phase 1	NA	[9]
House dust mite allergy vaccine	DM9JLIO	Phase 1	NA	[31]
IVN-201	DMPDYUS	Phase 1	NA	[32]
Ragweed pollen allergen sublingual immunotherapy	DM208RR	Phase 1	NA	[33]
SAR439794	DMLOKVW	Phase 1	NA	[9]
Timothy grass pollen extracts	DMS2U0H	Phase 1	NA	[34]
------------------------------------------------------------------------------------


⏷ Show the Full List of 33 Drug(s)

This Disease is Treated as An Indication in 29 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Terfenadine	DM4KLPT	Withdrawn from market	Small molecular drug	[35]
Allervax Ragweed	DMTAOAF	Discontinued in Phase 3	NA	[36]
Tagorizine	DMO3T26	Discontinued in Phase 3	Small molecular drug	[37]
BRL-61063	DMV3Y8R	Discontinued in Phase 2	Small molecular drug	[38]
Decapeptide allergy vaccine	DMT1UMJ	Discontinued in Phase 2	NA	[39]
TAK-201	DM8S173	Discontinued in Phase 2	NA	[40]
Talizumab	DMBM6US	Discontinued in Phase 2	Monoclonal antibody	[41]
VTX-2337	DMLCTBP	Discontinued in Phase 2	Small molecular drug	[42]
AGN-191743	DM8XODL	Discontinued in Phase 1	NA	[43]
AIR-Epinephrine	DMGAERX	Discontinued in Phase 1	NA	[44]
CY-1787	DMWY2NT	Discontinued in Phase 1	NA	[45]
DF-1111301	DMZYVFH	Discontinued in Phase 1	NA	[46]
DW-908e	DMXJ54Z	Discontinued in Phase 1	NA	[47]
TAK-683	DMRD8HK	Discontinued in Phase 1	Small molecular drug	[48]
A-93178	DM1KBAY	Terminated	NA	[50]
AA-861	DMPEB0Z	Terminated	Small molecular drug	[51]
AWD-72-011	DMK3MHJ	Terminated	NA	[52]
D-22888	DM7FTCV	Terminated	Small molecular drug	[53]
D-43787	DM0YFZ6	Terminated	Small molecular drug	[54]
KF-15766	DMNZ1LR	Terminated	NA	[55]
NPC-16570	DMG31N2	Terminated	Small molecular drug	[56]
Recombinant house dust mite allergy desensitization injection	DM2A6FZ	Terminated	NA	[57]
RWJ-22108	DMBXDQG	Terminated	Small molecular drug	[58]
Sch-40338	DM3G5IB	Terminated	Small molecular drug	[59]
Siguazodan	DM98K76	Terminated	Small molecular drug	[60]
TEI-9874	DMXM3B4	Terminated	NA	[61]
Tipredane	DMGCI6E	Terminated	Small molecular drug	[62]
TJ-127	DM2GLO9	Terminated	NA	[63]
WEB-2347	DMY9NG1	Terminated	Small molecular drug	[64]
------------------------------------------------------------------------------------


⏷ Show the Full List of 29 Drug(s)

This Disease is Treated as An Indication in 1 Preclinical Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
IMO-2134	DMXN2ZQ	Preclinical	NA	[49]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 30 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
ABX-301	DMBYIOJ	Investigative	NA	[65]
AFM-19	DMP952R	Investigative	NA	[65]
Ara-LAMP-vax	DMN6UIJ	Investigative	NA	[65]
Carbon nanospheres	DM3GUTJ	Investigative	NA	[65]
CAY 10471	DM4O69H	Investigative	Small molecular drug	[66]
EDP-14	DM4LYD2	Investigative	NA	[65]
HL-025	DMPQGTW	Investigative	NA	[65]
IGEL1.2	DMOU234	Investigative	Aptamer	[67]
Ii-key/MHC class II epitope hybrid peptides	DM7UZA2	Investigative	NA	[65]
IPP-201007	DMWJY1V	Investigative	NA	[65]
IPZ-010	DMSJDEN	Investigative	NA	[65]
IVN-mite	DMXYTTF	Investigative	NA	[65]
J-607Y	DMABP8B	Investigative	NA	[65]
J-775Y	DMLZFWF	Investigative	NA	[65]
Japanese cedar peptide allergy desensitization agent	DMCS92T	Investigative	NA	[65]
Japanese cedar pollen allergy sublingual immunotherapy	DMRB9OD	Investigative	NA	[65]
JDP-201	DMH8CEU	Investigative	NA	[65]
MB-11319	DM6VXRF	Investigative	NA	[65]
MK-6105	DM3T4QG	Investigative	NA	[65]
Oralgen Tree Pollen	DMOS5AG	Investigative	NA	[65]
RGI-1001	DMZN6EM	Investigative	NA	[65]
SC-01	DMOG48L	Investigative	NA	[65]
SC-02	DMLQARO	Investigative	NA	[65]
SF-107	DMD9LOG	Investigative	NA	[65]
SMT-14400	DM2GO5B	Investigative	NA	[65]
SRW-LAMP-vax	DMCANLF	Investigative	NA	[65]
UR-12510	DM2HVUW	Investigative	NA	[68]
VRT-750018	DMFT49S	Investigative	NA	[69]
XGP-510	DMBLR73	Investigative	NA	[70]
XGP-515	DMWVWQ2	Investigative	NA	[65]
------------------------------------------------------------------------------------


⏷ Show the Full List of 30 Drug(s)

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 44 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
AKR1B1	TTFBNVI	Limited	Biomarker	[71]
ALB	TTFNGC9	Strong	Biomarker	[72]
CASP1	TTCQIBE	Strong	Biomarker	[73]
CCL11	TTCF05Y	Strong	Biomarker	[73]
CCL17	TTMPHAE	Strong	Biomarker	[73]
CCL2	TTNAY0P	Strong	Biomarker	[73]
CCL20	TT2XAZY	Strong	Biomarker	[73]
CCL3	TT8I4WB	Strong	Biomarker	[74]
CCR1	TTC24WT	Strong	Biomarker	[73]
CCR2	TTFZYTO	Strong	Biomarker	[73]
CCR6	TTFDB30	Strong	Biomarker	[73]
CCR9	TTIPS8B	Strong	Biomarker	[73]
CD274	TT8ZLTI	Strong	Biomarker	[74]
CD40LG	TTIJP3Q	Strong	Biomarker	[73]
CSF2RA	TT6MP2Z	Strong	Biomarker	[75]
CX3CL1	TT1OFBQ	Strong	Biomarker	[73]
CXCL1	TTLK1RW	Strong	Biomarker	[73]
CXCL9	TTWE5PB	Strong	Biomarker	[73]
CXCR2	TT30C9G	Strong	Biomarker	[73]
CXCR3	TT1UCIJ	Strong	Biomarker	[73]
HLA-B	TTGS10J	Strong	Genetic Variation	[76]
HLA-DQA1	TTU2I3J	Strong	Biomarker	[77]
HLA-DRB1	TTUXSTW	Strong	Biomarker	[77]
HP	TTLC8E1	Strong	Biomarker	[78]
HTR2B	TT0K1SC	Strong	Biomarker	[79]
IL13	TT0GVCH	Strong	Biomarker	[73]
IL16	TTW4R0B	Strong	Biomarker	[74]
IL17A	TTG0MT6	Strong	Biomarker	[73]
IL18	TTRICUF	Strong	Biomarker	[73]
IL1R1	TTWOTEA	Strong	Biomarker	[73]
IL1R2	TT51DEV	Strong	Biomarker	[73]
IL2RB	TT9721Y	Strong	Biomarker	[73]
IL4	TTLGTKB	Strong	Biomarker	[73]
IL5RA	TTXH9AD	Strong	Biomarker	[73]
ITGB2	TTIJWR7	Strong	Biomarker	[73]
KNG1	TTDJ4MY	Strong	Biomarker	[80]
MTHFR	TTQWOU1	Strong	Biomarker	[81]
MYLK	TT18ETS	Strong	Biomarker	[82]
PF4	TTSG7Q5	Strong	Biomarker	[73]
SELP	TTE5VG0	Strong	Biomarker	[83]
SPP1	TT8ME6I	Strong	Biomarker	[73]
TNFRSF1A	TTG043C	Strong	Biomarker	[73]
TNFRSF1B	TT63WSF	Strong	Biomarker	[73]
TRPA1	TTELV3W	Strong	Biomarker	[84]
------------------------------------------------------------------------------------


⏷ Show the Full List of 44 DTT(s)

This Disease Is Related to 1 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
CYP1A1	DE6OQ3W	Limited	Biomarker	[85]
------------------------------------------------------------------------------------

This Disease Is Related to 18 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
LMAN1	OTYHKDEO	Limited	Biomarker	[86]
ABCF1	OT6Q079J	Strong	Biomarker	[73]
CCL19	OTQ2UJMH	Strong	Biomarker	[73]
CCL24	OT9LGHV0	Strong	Biomarker	[73]
CCL4	OT6B8P25	Strong	Biomarker	[73]
CCL7	OTDIS99H	Strong	Biomarker	[73]
CCL8	OTCTWYN8	Strong	Biomarker	[73]
CLEC4A	OTNLPK2C	Strong	Biomarker	[74]
COMMD1	OT7WUD5R	Strong	Biomarker	[87]
CXCL5	OTZOUPCA	Strong	Biomarker	[73]
DSG1	OT11HC3A	Strong	Biomarker	[88]
HLA-DQB1	OTVVI3UI	Strong	Biomarker	[77]
HLA-DRB4	OTNXIHQU	Strong	Biomarker	[77]
HLA-DRB5	OTUX5TWM	Strong	Biomarker	[77]
IL6ST	OT1N9C70	Strong	Biomarker	[73]
MAP2K6	OTK13JKC	Strong	Therapeutic	[89]
PPBP	OT1FHGQS	Strong	Biomarker	[74]
TAC1	OTM842YW	Strong	Biomarker	[80]
------------------------------------------------------------------------------------


⏷ Show the Full List of 18 DOT(s)

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 509).
3	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7216).
4	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1220).
5	Antinociception induced by central administration of histamine in the formalin test in rats. Indian J Physiol Pharmacol. 2008 Jul-Sep;52(3):249-54.
6	Clinical pipeline report, company report or official report of Merck.
7	Suplatast tosilate inhibits goblet-cell metaplasia of airway epithelium in sensitized mice. J Allergy Clin Immunol. 2000 Apr;105(4):739-45.
8	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010983)
9	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
10	ClinicalTrials.gov (NCT02040844) Phase III Cat-PAD Follow-on Study. U.S. National Institutes of Health.
11	ALK-Abell reports phase III results from US clinical study
12	Clinical pipeline report, company report or official report of Allergy Therapeutics plc.
13	ClinicalTrials.gov (NCT01012531) Efficacy and Safety of Specific Immunotherapy With CLUSTOID Grass Pollen. U.S. National Institutes of Health.
14	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025375)
15	Clinical pipeline report, company report or official report of Anergis SA.
16	ClinicalTrials.gov (NCT01855880) Phase IIa Study of Multiple Doses of AbGn-168H by iv Infusion in Moderate to Severe Chronic Plaque Psoriasis Patients. U.S. National Institutes of Health.
17	ClinicalTrials.gov (NCT01720251) Efficacy Study of a Preseasonal Treatment With AllerT in Subjects With Birch Pollen Allergy. U.S. National Institutes of Health.
18	Clinical pipeline report, company report or official report of Circassia.
19	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032688)
20	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035711)
21	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031733)
22	ClinicalTrials.gov (NCT01056783) Proof of Concept Study of OC000459 in Eosinophilic Esophagitis. U.S. National Institutes of Health.
23	The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72.
24	Clinical pipeline report, company report or official report of Circassia.
25	Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2008 Nov;122(5):951-60.
26	Clinical pipeline report, company report or official report of Shionogi (2011).
27	Clinical pipeline report, company report or official report of Greer Laboratories.
28	ClinicalTrials.gov (NCT01308294) Immunotherapy of HLA-A2 Positive Stage II-IV Melanoma Patients. U.S. National Institutes of Health.
29	Sublingual-oral administration of standardized allergenic extracts: phase 1 safety and dosing results. Ann Allergy Asthma Immunol. 2008 May;100(5):475-81.
30	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019601)
31	Clinical pipeline report, company report or official report of Circassia.
32	ClinicalTrials.gov (NCT00718679) Evaluation of Safety, Tolerability, Immunogenicity and Efficacy of a Novel Method in Specific Immunotherapy in Cat Allergic Patients: a Placebo Controlled Trial. U.S.National Institutes of Health.
33	ClinicalTrials.gov (NCT01224834) Safety and Tolerability Study of Ragweed SLIT Tablets. U.S. National Institutes of Health.
34	A Phase I clinical trial with subcutaneous immunotherapy vaccine of Timothy grass pollen extract according to EMA guidelines. Immunotherapy. 2015;7(4):343-52.
35	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2608).
36	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006736)
37	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002636)
38	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004678)
39	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004696)
40	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031068)
41	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012521)
42	ClinicalTrials.gov (NCT01666444) VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer. U.S. National Institutes of Health.
43	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003636)
44	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019414)
45	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003725)
46	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003701)
47	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020029)
48	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3325).
49	Clinical pipeline report, company report or official report of Idera Pharmaceuticals (2011).
50	Characterization of A-93178, an iminoxy-quinoline inhibitor of leukotriene biosynthesis. Adv Exp Med Biol. 1997;433:91-4.
51	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000099)
52	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013995)
53	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007179)
54	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010545)
55	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005087)
56	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005351)
57	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015369)
58	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002359)
59	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1854).
60	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000375)
61	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012536)
62	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003182)
63	Effectiveness of Mao-bushi-saishin-to in Treating Common Cold Syndrome. Controlled Comparative Study Using the Sealed Envelope Method. Kampo Medicine 1996, 47(2): 245-252.
64	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001720)
65	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
66	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 339).
67	Therapeutic applications of aptamers. Expert Opin Investig Drugs. 2008 Jan;17(1):43-60.
68	US patent application no. 6,673,908, Tumor necrosis factor receptor 2.
69	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2230).
70	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 269).
71	Aldose reductase inhibitor zopolrestat restores allergic hyporesponsiveness in alloxan-diabetic rats.Eur J Pharmacol. 2006 Nov 7;549(1-3):173-8. doi: 10.1016/j.ejphar.2006.08.037. Epub 2006 Aug 26.
72	Adverse reactions to human serum albumin.Ann Pharmacother. 1993 Jan;27(1):87-94. doi: 10.1177/106002809302700119.
73	Expansion of CD4(+) CD25(+) and CD25(-) T-Bet, GATA-3, Foxp3 and RORt cells in allergic inflammation, local lung distribution and chemokine gene expression.PLoS One. 2011;6(5):e19889. doi: 10.1371/journal.pone.0019889. Epub 2011 May 19.
74	Evaluation of selected biomarkers for the detection of chemical sensitization in human skin: a comparative study applying THP-1, MUTZ-3 and primary dendritic cells in culture. Toxicol In Vitro. 2013 Sep;27(6):1659-69. doi: 10.1016/j.tiv.2013.04.009. Epub 2013 Apr 26.
75	GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia.Blood. 2013 Jun 20;121(25):5068-77. doi: 10.1182/blood-2012-10-460170. Epub 2013 Apr 30.
76	Genome-wide association study of nevirapine hypersensitivity in a sub-Saharan African HIV-infected population.J Antimicrob Chemother. 2017 Apr 1;72(4):1152-1162. doi: 10.1093/jac/dkw545.
77	[Analysis of a genetic factor of metal allergy--polymorphism of HLA-DR, -DQ gene].Kokubyo Gakkai Zasshi. 1996 Mar;63(1):53-69. doi: 10.5357/koubyou.63.53.
78	Iron and infection: effects of host iron status and the iron-regulatory genes haptoglobin and NRAMP1 (SLC11A1) on host-pathogen interactions in tuberculosis and HIV.Clin Sci (Lond). 2006 May;110(5):503-24. doi: 10.1042/CS20050273.
79	5-HT(2B) receptors play a key role in mediating the excitatory effects of 5-HT in human colon in vitro.Br J Pharmacol. 2002 Mar;135(5):1144-51. doi: 10.1038/sj.bjp.0704571.
80	Chronic tobacco smoke exposure increases airway sensitivity to capsaicin in awake guinea pigs.J Appl Physiol (1985). 2001 Feb;90(2):695-704. doi: 10.1152/jappl.2001.90.2.695.
81	The association between atopy and factors influencing folate metabolism: is low folate status causally related to the development of atopy?.Int J Epidemiol. 2006 Aug;35(4):954-61. doi: 10.1093/ije/dyl094. Epub 2006 Jun 9.
82	Acute stress-induced hypersensitivity to colonic distension depends upon increase in paracellular permeability: role of myosin light chain kinase.Pain. 2005 Jan;113(1-2):141-7. doi: 10.1016/j.pain.2004.10.002.
83	Novel case-control test in a founder population identifies P-selectin as an atopy-susceptibility locus.Am J Hum Genet. 2003 Sep;73(3):612-26. doi: 10.1086/378208. Epub 2003 Aug 15.
84	TRPA1 receptor localisation in the human peripheral nervous system and functional studies in cultured human and rat sensory neurons.Neurosci Lett. 2008 Jun 20;438(2):221-7. doi: 10.1016/j.neulet.2008.04.007. Epub 2008 Apr 8.
85	Relation of PON1 and CYP1A1 genetic polymorphisms to clinical findings in a cross-sectional study of a Greek rural population professionally exposed to pesticides.Toxicol Lett. 2009 Apr 10;186(1):66-72. doi: 10.1016/j.toxlet.2008.10.018. Epub 2008 Oct 28.
86	Role of collectins in innate immunity against aspergillosis.Med Mycol. 2005 May;43 Suppl 1:S155-63. doi: 10.1080/13693780500088408.
87	Liver-specific Commd1 knockout mice are susceptible to hepatic copper accumulation.PLoS One. 2011;6(12):e29183. doi: 10.1371/journal.pone.0029183. Epub 2011 Dec 22.
88	Desmoglein 1 deficiency results in severe dermatitis, multiple allergies and metabolic wasting. Nat Genet. 2013 Oct;45(10):1244-1248. doi: 10.1038/ng.2739. Epub 2013 Aug 25.
89	A novel DC therapy with manipulation of MKK6 gene on nickel allergy in mice.PLoS One. 2011 Apr 22;6(4):e19017. doi: 10.1371/journal.pone.0019017.